Brazil ANVISA SaMD & AI Vigilance Rules: Mid-October 2026 Feedback Deadline

Brazil's ANVISA has launched Public Call No. 4/2026 to revise its Tecnovigilância (post-market vigilance) framework, specifically seeking industry feedback on the challenges posed by Software as a Medical Device (SaMD) and AI. This episode breaks down the proposal, who is affected, and the urgent mid-October 2026 deadline for manufacturers to submit comments and influence the future of digital health regulation in this key Latin American market. Key Questions: - What is ANVISA's Public Call No. 4/2026 and why is it critical for SaMD manufacturers? - How are AI and machine learning changing the requirements for post-market vigilance in Brazil? - What specific challenges has ANVISA identified for software-based medical devices? - What is the exact deadline for submitting feedback to influence these new regulations? - How can manufacturers effectively prepare and submit their comments to ANVISA? - What are the potential consequences of not participating in this public consultation? - What practical steps should your regulatory team take right now before the mid-October 2026 deadline? Sources: - https://www.youtube.com/watch?v=your_video_id How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative and Brazil Registration Holder (BRH), managing the entire lifecycle from regulatory strategy and technical dossier submission to post-market surveillance. Our team of local experts, supported by advanced AI tools, can help you analyze ANVISA's proposed changes, formulate an effective response to Public Call No. 4/2026, and ensure your products maintain compliance in over 30 markets worldwide. To learn how we can accelerate your market access, visit https://pureglobal.com, contact us at [email protected], or explore our free regulatory AI tools and database at https://pureglobal.ai.